Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Study of ASP2957 in X-linked Myotubular Myopathy
NCT07876804Phase 2Not yet recruiting
- Sponsor
- Astellas Gene Therapies
- Start
- Oct 2026
- Primary completion
- Jul 2032
01
Overview
A Phase 2 trial of ASP2957 in X-linked myotubular myopathy (XLMTM), sponsored by Astellas Gene Therapies. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ASP2957
03
Conditions
X-linked myotubular myopathy (XLMTM)
Beyond the preview
Go deeper on NCT07876804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07876804.